Reply to N. Okano et al

被引：0

作者：

Ramaswamy, Anant ^{[1
]}

Ostwal, Vikas ^{[1
]}

机构：

[1] Tata Mem Hosp, Mumbai, India

来源：

关键词：

D O I：

10.1200/JCO.24.00126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3

共 2 条

[1] Promising Objective Response Rates and Progression-Free Survival but Modest Overall Survival in the TAB Study
Okano, Naohiro
Mizutani, Tomonori
Hironaka, Shuichi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14)
[2] Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)
Ostwal, Vikas
Mandavkar, Sarika
Bhargava, Prabhat
Srinivas, Sujay
Kapoor, Akhil
Shetty, Omshree
Kannan, Sadhana
Chaugule, Deepali
Patil, Rajshree
Parulekar, Manali
Nashikkar, Chaitali
Ankathi, Suman Kumar
Baheti, Akshay Dwarka
Mehta, Daksha
Kaushal, Rajiv Kumar
Yadav, Subhash
Shah, Aekta
Patkar, Shraddha
Goel, Mahesh
Ramaswamy, Anant
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (07) : 800 - 807